You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中国生物制药(01177.HK)组合营开发抗肿瘤项目
阿思达克 06-18 05:11

中国生物制药(01177.HK)公布,附属正大天晴与中山康方生物医药成立合营,共同开发重组人源化抗PD-1单克隆抗体AK105项目,并全力推动该药物的注册上市及产业化进程。

合营注册资本6.89亿人民币,双方分别持股50%。其中,正大天晴将以现金出资近3.45亿人民币,康方生物将以其AK105项目的知识产权和相关技术的全部权益作为无形资产出资。

AK105是前期由康方生物自主研发的重组人源化抗 PD-1 单克隆抗体,项目已完成在澳洲的I期爬坡试验和在中国的I期临床试验,显示了稳定的药代动力学特徵和可喜的初步抗肿瘤有效性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account